ArticleInternational journal of bioprinting2023
Performance of hybrid gelatin-PVA bioinks integrated with genipin through extrusion-based 3D bioprinting: An
Article in International journal of bioprinting, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Emerging Nano Bioinks in Bioprinting: Functional Materials, Engineering Strategies, and Biomedical Applications.Materials (Basel, Switzerland) · 2026Review
- Fabrication of levan derived fromSynthetic and systems biotechnology · 2026Article
- Engineering Functional PVA: A Comprehensive Review of Chemical Modifications and Prospective Developments.ACS polymers Au · 2026Review
- Kelulut Honey-Incorporated Hybrid Gelatin-PVA Hydrogel for Wound Healing: Fabrication and In Vitro Characterization.Polymers · 2025Article
- Bioprinting for drug screening: A path toward reducing animal testing or redefining preclinical research?Bioactive materials · 2025Review
- Enhancing Wound Healing Through Secretome-Loaded 3D-Printed Biomaterials.Gels (Basel, Switzerland) · 2025Review
- Article
- Physicochemical Characterization of Injectable Genipin-Crosslinked Gelatin-Kelulut Honey Hydrogels for Future Cutaneous Tissue Loss.Polymers · 2025Article
- A Comprehensive Review of Honey-Containing Hydrogel for Wound Healing Applications.Gels (Basel, Switzerland) · 2025Review
- Bioprinting vascularized skin analogs: a stepwise approach.Burns & trauma · 2025Review
- The sculpting tool in bioprinting: research and application progress of sacrificial inks.Frontiers in bioengineering and biotechnology · 2025Review
- Article
- Article
- Dual Crosslinked Antioxidant Mixture of Poly(vinyl alcohol) and Cerium Oxide Nanoparticles as a Bioink for 3D Bioprinting.ACS applied nano materials · 2024Review
- Poly(Vinyl Alcohol)/Bovine Serum Albumin Hybrid Hydrogels with Tunable Mechanical Properties.Polymers · 2023Article
- Human epidermal keratinocytes and human dermal fibroblasts interactions seeded on gelatin hydrogel for future application in skinFrontiers in bioengineering and biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3D bioprinting technology is a well-established and promising advanced fabrication technique that utilizes potential biomaterials as bioinks to replace lost skin and promote new tissue regeneration. Cutaneous regenerative biomaterials are highly commended since they benefit patients with larger wound sizes and irregular wound shapes compared to the painstaking split-skin graft. This study aimed to fabricate biocompatible, biodegradable, and printable bioinks as a cutaneous substitute that leads to newly formed tissue post-transplantation. Briefly, gelatin (GE) and polyvinyl alcohol (PVA) bioinks were prepared in various concentrations (w/v); GE (6% GE: 0% PVA), GPVA3 (6% GE: 3% PVA), and GPVA5 (6% GE: 5% PVA), followed by 0.1% (w/v) genipin (GNP) crosslinking to achieve optimum printability. According to the results, GPVA5_GNP significantly presented at least 590.93 ± 164.7% of swelling ratio capacity and optimal water vapor transmission rate (WVTR), which is <1500 g/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.